SavedAdd your journal

Journals / Hitit Medical Journal / 2026 / Cilt: 8 Sayı: 2

Genotypic Profiles and Prevalence of Human Papillomavirus: A Single-Center Study from Ankara, Türkiye

İnsan Papilloma Virüsünün Genotipik Profilleri ve Prevalansı: Ankara, Türkiye’den Tek Merkezli Bir Çalışma

Ülker Çuhacı(YÜKSEK İHTİSAS ÜNİVERSİTESİ)0000-0002-6420-6185
Etem Özkaya0009-0003-0755-7418
Bilal Özdemir(YÜKSEK İHTİSAS ÜNİVERSİTESİ)0000-0003-0708-7332
Pages
222–235
Publication Date
2026-06-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Types 6, 16, and 66 were the most common genotypes, with Type 6 being more common in younger patients and Types 16 and 66 predominating among those aged 35–44.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate the prevalence of human papillomavirus (HPV) infections and the distribution of HPV genotypes according to gender and age by retrospectively analyzing HPV test results from 2021 to 2023.
📊
Key Findings & Data:Methods: HPV-DNA test results obtained from liquid-based cytology (LBC) and tissue samples of symptomatic patients (≥18 years of age) referred to the Microbiology Laboratory of Özkaya Medical Center between 2021 and 2023 were retrospectively reviewed through the hospital information system.
💡
Conclusion & Impact:Types 6, 16, and 66 were the most common genotypes, with Type 6 being more common in younger patients and Types 16 and 66 predominating among those aged 35–44.
🔬Design:Review & Systematic Survey
📍Scope:2021 Verileri
⚙️Variables:İnsan papillomavirüs · Servikal kanser taraması · Genotip

Abstract

Objective: This study aimed to investigate the prevalence of human papillomavirus (HPV) infections and the distribution of HPV genotypes according to gender and age by retrospectively analyzing HPV test results from 2021 to 2023. Methods: HPV-DNA test results obtained from liquid-based cytology (LBC) and tissue samples of symptomatic patients (≥18 years of age) referred to the Microbiology Laboratory of Özkaya Medical Center between 2021 and 2023 were retrospectively reviewed through the hospital information system. A total of 692 patient results were included. Statistical analyses were performed using IBM SPSS Statistics version 27.0. Fisher’s exact test was applied for categorical variables, with data presented as number (n) and percentage (%). A p-value of <0.05 was considered statistically significant. Results: The most frequent HPV genotypes detected were Types 6 and 16. Among female patients, Types 6, 16, and 66 were most common. HPV DNA positivity was identified in 545 female patients and in 2 male patients. Type 6 was mainly observed in patients under 25 and those aged 25–29, while Types 16 and 66 were more frequent in the 35–39 and 40–44 age groups. In general, HPV DNA-positive patients were concentrated in the 35–39 and 40–44 age ranges, whereas HPV DNA-negative patients were mostly between 30–34 years. Conclusion: HPV infections were significantly more prevalent in women than in men. Types 6, 16, and 66 were the most common genotypes, with Type 6 being more common in younger patients and Types 16 and 66 predominating among those aged 35–44.

Özet

Amaç: Bu çalışmada, 2021–2023 yılları arasında elde edilen HPV test sonuçları retrospektif olarak incelenerek insan papillomavirüs (HPV) enfeksiyonlarının prevalansının yanı sıra HPV genotiplerinin cinsiyet ve yaşa göre dağılımının araştırılması amaçlanmıştır. Yöntemler: Çalışmaya, 2021–2023 yılları arasında Özkaya Tıp Merkezi Mikrobiyoloji Laboratuvarı’na başvuran ≥18 yaş semptomatik hastalardan alınan sıvı bazlı sitoloji (LBC) ve doku örneklerine ait HPV-DNA test sonuçları dâhil edilmiştir. Toplam 692 hasta sonucu hastane bilgi sistemi üzerinden retrospektif olarak değerlendirilmiştir. İstatistiksel analizler IBM SPSS Statistics versiyon 27.0 programı kullanılarak yapılmıştır. Kategorik değişkenler için Fisher’s exact testi uygulanmış; veriler sayı (n) ve yüzde (%) olarak sunulmuştur. p<0,05 değeri istatistiksel olarak anlamlı kabul edilmiştir. Bulgular: En sık saptanan HPV genotipleri Tip 6 ve Tip 16 olmuştur. Kadın hastalarda en yaygın olarak Tip 6, 16 ve 66 belirlenmiştir. HPV DNA pozitifliği 545 kadın ve 2 erkek hastada saptanmıştır. Tip 6 daha çok 25 yaş altı ve 25–29 yaş grubunda görülürken, Tip 16 ve Tip 66’nın 35–39 ve 40–44 yaş gruplarında daha sık olduğu belirlenmiştir. Genel olarak HPV DNA pozitif olgular 35–39 ve 40–44 yaş aralıklarında yoğunlaşırken, HPV DNA negatif olguların çoğunlukla 30–34 yaş grubunda olduğu görülmüştür. Sonuç: HPV enfeksiyonlarının kadınlarda erkeklere kıyasla anlamlı derecede daha yaygın olduğu saptanmıştır. En sık rastlanan genotipler Tip 6, 16 ve 66 olup; Tip 6 genç yaş grubunda, Tip 16 ve 66 ise 35–44 yaş aralığında daha baskın bulunmuştur.

🔖

Cite This Article

Çuhacı, Ü., Özkaya, E., Özdemir, B. (2026). Genotypic Profiles and Prevalence of Human Papillomavirus: A Single-Center Study from Ankara, Türkiye. Hitit Medical Journal, Cilt: 8 Sayı: 2, 222–235. https://doi.org/10.52827/hititmedj.1788958

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (48)

  1. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res 2017;231:119-127.
  2. Şahiner F, Şener K. Human Papilloma Virüs Enfeksiyonları, Risk Faktörleri ve Koruyucu Önlemler. TAF Prev Med Bull 2013;12(6):715-722.
  3. Selçuk AK, Yanıkkerem E. Serviks Kanseri ve Human Papillomavirus (HPV) Prevalansı ile HPV Aşı Programları. Kadın Sağlığı Hemşireliği Dergisi 2018;4(2):40-55.
  4. Hathaway JK. HPV: diagnosis, prevention, and treatment. Clin Obstet Gynecol 2012;55(3):671-680.
  5. Eroğlu C, Kesli R, Eryılmaz MA, Unlü Y, Gönenç O. The types and the relation of HPV prevalence to risk factors and cervical smear in women at risk for cervical cancer. Nobel Med 2011;7(3):72-77.
  6. Çeşmeci Y, Köylü B, Sulaiman J, et al. İnternlerin Gözünden HPV Enfeksiyonları ve HPV Aşısı. Türk Jinekolojik Onkoloji Dergisi 2015;18(3):85-92.
  7. Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2015;61(Suppl 8):S849-S855.
  8. Başar F, Çiçek S, Sağlam H. Hemşirelik Bölümü Öğrencilerinin Human Papilloma Virüsü ve Aşısına Yönelik Bilgi Düzeyleri. Uluslararası Toplum Araştırmaları Dergisi 2019:125-133.
  9. İşgüder Ç, Oktay G, Doğru H, et al. Sağlık Yüksekokulu Öğrencilerinin HPV Aşısı Bilgi Düzeyinin Değerlendirilmesi. J Contemp Med 2017;7(1):1-7.
  10. Koçak C, Çelebi Erkılıç M. İnsan Papilloma Virüsü (HPV) enfeksiyonları ve HPV aşılamasında güncel yaklaşımlar. Toplum ve Hekim 2024;39(4).
  11. Özdemir J, Yücel M, Kızılkaya S, et al. HPV, HPV vaccination worldwide and current status of HPV vaccination in Turkey: a literature review. Turk Med Stud J 2022;9(2):48-54.
  12. Özdemir K, Şahin S, Ünsal A. Üniversitede öğrenim gören kız öğrencilerin HPV bilgi düzeyinin incelenmesi (Sakarya, Türkiye). Kadın Cinsel Sağlığı 2021;23:97-104.
  13. Gök S, Gök B, Ceylan D. HPV-16/18 pozitif kadınların takibinde kolposkopi eşliğinde alınan servikal biyopsinin önemi. Pamukkale Tıp Dergisi 2021;14:253-261.
  14. Wolf J, Kist LF, Pereira SB, et al. Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol 2024;34(3):e2537.
  15. Cangöl E, Sögüt S, Süt HK, Küçükkaya B. Knowledge and attitudes of nursing students concerning HPV vaccination. J Hum Sci 2019;16(1):1-12.
  16. Aldıkaçtıoğlu Talmaç M, Vural NA, Satılmışoğlu ZZ, Hocagil FZ, Atasoy Rusen M, Çetinkaya N. Knowledge level about HPV infection and cervical cancer screening tests. J Contemp Med 2023;13(5):949-953.
  17. Açikgöz A, Ergör G. Cervical cancer risk levels in Turkey and compliance to the national cervical cancer screening standard. Asian Pac J Cancer Prev 2011;12(4):923-927.
  18. Kıran Ş, Akbolat M. Perceived barriers and facilitators in access to breast and cervical cancer screening: a qualitative exploration among women in Trabzon, Turkey. J Health Organ Manag 2026;40(1):107-123.
  19. Kulhan M, Kulhan NG, Seven Y, et al. Estimation of the prevalence and distribution of HPV genotypes and identification of related risk factors among Turkish women. Contemp Oncol (Pozn) 2017;21(3):218-223.
  20. Letafati A, Motlaghzadeh S, Ardekani OS, et al. Uncommon high distribution of HPV-16, HPV-54, and HPV-56 in female referred to a laboratory in Karaj, Iran: indications of a paradigm shift in HPV genotypes? Virol J 2024;21(1):182.
  21. Fogarasi AI, Benczik M, Moravcsik-Kornyicki Á, et al. The prevalence of high-risk human papillomavirus in Hungary: a geographically representative, cross-sectional study. Pathol Oncol Res 2022;28:1610424.
  22. Mkrtchian L, Zamulaeva I, Krikunova L, et al. HPV status and individual characteristics of human papillomavirus infection as predictors for clinical outcome of locally advanced cervical cancer. J Pers Med 2021;11(6):479.
  23. Argyri E, Tsimplaki E, Papatheodorou D, Daskalopoulou D, Panotopoulou E. Recent trends in HPV infection and type distribution in Greece. Anticancer Res 2018;38(5):3079-3084.
  24. Bakhshani A, Ganjali R, Tabatabaeizadeh SE. Prevalence of human papillomavirus (HPV) genotypes among women during 2015-2020 in Mashhad, Iran. Arch Iran Med 2023;26(8):419-426.
  25. Baddal B, Oktay MN, Bostanci A, Yenen MC. Prevalence and genotype screening of human papillomavirus among women attending a private hospital in Northern Cyprus: an 11-year retrospective study. BMC Womens Health 2023;23(1):297.
  26. Nikolic N, Basica B, Strbac M, et al. Prevalence of carcinogenic genotypes of HPV-infected women in a ten-year period (2014-2023) in Vojvodina, Serbia. Medicina 2024;60(6):922.
  27. Ciurescu S, Ioan S, Gorun FI, et al. Pap cytology and human papillomavirus (HPV) genotypes in Western Romania: a retrospective analysis. Cureus 2024;16(7).
  28. Dovey de la Cour C, Guleria S, Nygård M, et al. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women: Potential for prevention. Cancer Med 2019;8(2):839-849.
  29. Denny L, Adewole I, Anorlu R, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer 2014;134(6):1389-1398.
  30. Tan SC, Ismail MP, Duski DR, Othman NH, Ankathil R. Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. Biosci Rep 2018;38(2):BSR20171268.
  31. Iljazović E, Mena M, Tous S, et al. Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina. Cancer Epidemiol 2014;38(5):504-510.
  32. Erdiren N, Atik TK, Turan G, Şener AG. High-risk HPV genotype distribution and prevalence in cervical swabs from Western Turkey. Diagn Microbiol Infect Dis 2026;114(2):117132.
  33. Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer 2018;142(9):1952-1958.
  34. Arslan HN, Oruc MA. Results from a cervical cancer screening program in Samsun, Turkey. BMC Womens Health 2022;22(1):331.
  35. Othman A, Goreal A, Pity I. Molecular detection of human papillomaviruses in formalin fixed paraffin embedded sections from different anogenital lesions in Duhok-Iraq. Diagnostics 2022;12(10):2496.
  36. Teka B, Gizaw M, Ruddies F, et al. Population-based human papillomavirus infection and genotype distribution among women in rural areas of South-Central Ethiopia. Int J Cancer 2021;148(3):723-730.
  37. Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer 2019;125(7):1030-1037.
  38. Turhan EI, Nalbant M, Bayrak M. Sıvı Bazlı Sitoloji, HPV-DNA Genotiplendirme ve Kolposkopik Biyopsi Sonuçlarının Değerlendirilmesi: 407 Vakanın Analizi. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 2022;9(3):204-207.
  39. Oyardı P, Dağıstanlı F, Albayrak ME, Kayhan M, Ekici MA. HPV prevalence and risk of premalignant and malignant lesions in women with asymptomatic cervical erosion: a population-based study. Abant Med J 2023;12(3):207-212.
  40. Dursun P, Ayhan A, Mutlu L, et al. HPV types in Turkey: Multicenter hospital based evaluation of 6388 patients in Turkish Gynecologic Oncology Group centers. Turk Patoloji Derg 2013;29(3).
  41. Teka B, Gizaw M, Ruddies F, et al. Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia. Int J Cancer 2021;148(3):723-730.
  42. Kazancı F, Koçak A, Çolak M, Erdem Ö, Onan M, Bozdayı G. Should we accept the HPV type 66 into a probable high-risk group? The prevalence, clinical and histopathological evaluation of HPV type 66 in Gazi University, Ankara. Gazi Med J 2021;32(1):98-103.
  43. Bergqvist L, Kalliala I, Aro K, et al. Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women. Microorganisms 2021;9(4):750.
  44. Valasoulis G, Pouliakis A, Michail G, et al. Cervical HPV Infections, Sexually Transmitted Bacterial Pathogens and Cytology Findings—A Molecular Epidemiology Study. Pathogens 2023;12(11):1347.
  45. Grandahl M, Larsson M, Dalianis T, et al. Catch-up HPV vaccination status of adolescents in relation to socioeconomic factors, individual beliefs and sexual behaviour. PLoS One 2017;12(11):e0187193.
  46. Egli-Gany D, Spaar Zographos A, Diebold J, et al. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer 2019;19(1):111.
  47. Osazuwa-Peters N, Adjei Boakye E, Rohde RL, et al. Understanding of risk factors for the human papillomavirus (HPV) infection based on gender and race. Sci Rep 2019;9(1):297.
  48. Ruan Y, Li H, Liu M, et al. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine. Cancer Epidemiol 2023;84:102372.